Fusion Inhibitors Market Size is predicted to witness a 13.6% CAGR during the forecast period for 2023-2031.
Fusion inhibitors use antiretroviral medications that act on the surface of host CD4 cells to prevent HIV infection. Fusion inhibitors bind an envelope protein, and the structural modifications required for virus fusion with the host CD4 cell are halted. Increased illness incidence, better early detection methods, more research into effective therapies, and higher demands for targeted medications. As a result, this is expected to be a major contributor to the growth of the fusion inhibitors market. In addition, Fusion inhibitors are widely used to treat HIV/AIDS. Enfuvirtide is an HIV fusion inhibitor that prevents the virus's fusion with the host's CD4+ T cells. This inhibits viral replication and slows the course of the disease.
Moreover, research into the effectiveness of fusion inhibitors in blocking viral entrance and replication is being conducted for other viral illnesses, including respiratory syncytial virus and herpes virus. The World Health Organization (WHO) estimates that there are currently 38 Mn people living with HIV/AIDS globally. Fusion inhibitors are a promising new class of antiretroviral drugs that offer patients new opportunities for better health and longer lives among those with HIV. Opportunities for the fusion inhibitors market to grow due to rising treatment rates. Over the projected period, the fusion inhibitors market's revenue will rise substantially as market players develop and release new products.
However, due to the public's lack of knowledge and the products' prohibitive prices, the fusion inhibitors medicines industry is expected to slow down shortly. The global inhibitors medications supply chain was severely impacted by the COVID-19 epidemic, which profoundly impacted people's and businesses' daily routines.
The fusion inhibitors market is segmented based on route of administration, indication, and distribution channel. Based on the route of administration, parenteral and oral. By indication, the market is segmented into HIV/AIDS and COVID-19. The market is segmented as per the distribution channel into retail pharmacies, online Pharmacies, and others.
The COVID-19 fusion inhibitors category is expected to hold a major global market share. This is attributed to the fact that there are now more people than ever with infectious disorders like COVID-19 infection.
The retail pharmacies segment is projected to grow rapidly in the global fusion inhibitors market. The rising need for antiviral medications has contributed to this trend in wealthy nations, especially in countries like the US, Germany, the UK, China, and India.
The North American fusion inhibitors market is expected to record the maximum market share in revenue in the near future. It can be attributed to establishing a cutting-edge healthcare infrastructure, the public's growing familiarity with curative drugs, and reimbursement regulations that are helpful to businesses. The market's growth is expected to continue during the projected period because of the government's increased spending on HIV prevention and treatment initiatives. In addition, Asia Pacific is estimated to grow rapidly in the global fusion inhibitors market because of increasing numbers of people being diagnosed with HIV disease, quickly expanding healthcare infrastructure, and rising healthcare expenses.
|
Report Attribute |
Specifications |
|
Growth Rate CAGR |
CAGR of 13.6% from 2023 to 2031 |
|
Quantitative Units |
Representation of revenue in US$ Bn and CAGR from 2023 to 2031 |
|
Historic Year |
2019 to 2022 |
|
Forecast Year |
2023-2031 |
|
Report Coverage |
The forecast of revenue, the position of the company, the competitive market structure, growth prospects, and trends |
|
Segments Covered |
By Route of Administration, Indication, Distribution Channel |
|
Regional Scope |
North America; Europe; Asia Pacific; Latin America; Middle East & Africa |
|
Country Scope |
U.S.; Canada; U.K.; Germany; China; India; Japan; Brazil; Mexico; France; Italy; South Korea; South East Asia |
|
Competitive Landscape |
Bristol-Myers Squibb Company, PeptidePharma, Incyte, AstraZeneca, ViiV Healthcare Limited, Frontier Bio Corporation, Trimeris, Inc., Progenics Pharmaceuticals, Schering-Plough (Merck & Co.), Biogen, Vanderbilt University, and Genentech. |
|
Customization Scope |
Free customization report with the procurement of the report, Modifications to the regional and segment scope. Particular Geographic competitive landscape. |
|
Pricing And Available Payment Methods |
Explore pricing alternatives that are customized to your particular study requirements. |
Chapter 1. Methodology and Scope
1.1. Research Methodology
1.2. Research Scope & Assumptions
Chapter 2. Executive Summary
Chapter 3. Global Fusion Inhibitors Market Snapshot
Chapter 4. Global Fusion Inhibitors Market Variables, Trends & Scope
4.1. Market Segmentation & Scope
4.2. Drivers
4.3. Challenges
4.4. Trends
4.5. Investment and Funding Analysis
4.6. Industry Analysis – Porter’s Five Forces Analysis
4.7. Competitive Landscape & Market Share Analysis
4.8. Impact of Covid-19 Analysis
Chapter 5. Market Segmentation 1: By Route of Administration Estimates & Trend Analysis
5.1. By Route of Administration, & Market Share, 2020 & 2031
5.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2020 to 2031 for the following By Route of Administration:
5.2.1. Parenteral
5.2.2. Oral
Chapter 6. Market Segmentation 2: By Indication Estimates & Trend Analysis
6.1. By Indication & Market Share, 2020 & 2031
6.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2020 to 2031 for the following By Indication:
6.2.1. HIV/AIDS
6.2.2. COVID-19
Chapter 7. Market Segmentation 3: By Distribution Channel Estimates & Trend Analysis
7.1. By Distribution Channel & Market Share, 2020 & 2031
7.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2020 to 2031 for the following By Distribution Channel:
7.2.1. Retail Pharmacies
7.2.2. Online Pharmacies
7.2.3. Others
Chapter 8. Fusion Inhibitors Market Segmentation 4: Regional Estimates & Trend Analysis
8.1. North America
8.1.1. North America Fusion Inhibitors Market revenue (US$ Million) estimates and forecasts By Route of Administration, 2019-2031
8.1.2. North America Fusion Inhibitors Market revenue (US$ Million) estimates and forecasts By Indication, 2019-2031
8.1.3. North America Fusion Inhibitors Market revenue (US$ Million) estimates and forecasts By Distribution Channel, 2019-2031
8.1.4. North America Fusion Inhibitors Market revenue (US$ Million) estimates and forecasts by country, 2019-2031
8.2. Europe
8.2.1. Europe Fusion Inhibitors Market revenue (US$ Million) By Route of Administration, 2019-2031
8.2.2. Europe Fusion Inhibitors Market revenue (US$ Million) By Indication, 2019-2031
8.2.3. Europe Fusion Inhibitors Market revenue (US$ Million) By Distribution Channel, 2019-2031
8.2.4. Europe Fusion Inhibitors Market revenue (US$ Million) by country, 2019-2031
8.3. Asia Pacific
8.3.1. Asia Pacific Fusion Inhibitors Market revenue (US$ Million) By Route of Administration, 2019-2031
8.3.2. Asia Pacific Fusion Inhibitors Market revenue (US$ Million) By Indication, 2019-2031
8.3.3. Asia Pacific Fusion Inhibitors Market revenue (US$ Million) By Distribution Channel, 2019-2031
8.3.4. Asia Pacific Fusion Inhibitors Market revenue (US$ Million) by country, 2019-2031
8.4. Latin America
8.4.1. Latin America Fusion Inhibitors Market revenue (US$ Million) By Route of Administration, (US$ Million) 2019-2031
8.4.2. Latin America Fusion Inhibitors Market revenue (US$ Million) By Indication, (US$ Million) 2019-2031
8.4.3. Latin America Fusion Inhibitors Market revenue (US$ Million) By Distribution Channel, (US$ Million) 2019-2031
8.4.4. Latin America Fusion Inhibitors Market revenue (US$ Million) by country, 2019-2031
8.5. Middle East & Africa
8.5.1. Middle East & Africa Fusion Inhibitors Market revenue (US$ Million) By Route of Administration, (US$ Million) 2019-2031
8.5.2. Middle East & Africa Fusion Inhibitors Market revenue (US$ Million) By Indication, (US$ Million) 2019-2031
8.5.3. Middle East & Africa Fusion Inhibitors Market revenue (US$ Million) By Distribution Channel, (US$ Million) 2019-2031
8.5.4. Middle East & Africa Fusion Inhibitors Market revenue (US$ Million) by country, 2019-2031
Chapter 9. Competitive Landscape
9.1. Major Mergers and Acquisitions/Strategic Alliances
9.2. Company Profiles
9.2.1. Bristol-Myers Squibb Company
9.2.2. PeptidePharma
9.2.3. Incyte
9.2.4. Astrazeneca
9.2.5. ViiV Healthcare Limited
9.2.6. Frontier Bio Corporation
9.2.7. Trimeris, Inc.
9.2.8. Progenics Pharmaceuticals
9.2.9. Schering-Plough (Merck & Co.)
9.2.10. Biogen
9.2.11. Vanderbilt University
9.2.12. Genentech
Fusion Inhibitors Market By Route of Administration -
Fusion Inhibitors Market By Indication -
Fusion Inhibitors Market By Distribution Channel -
Fusion Inhibitors Market By Region-
North America-
Europe-
Asia-Pacific-
Latin America-
Middle East & Africa-
InsightAce Analytic follows a standard and comprehensive market research methodology focused on offering the most accurate and precise market insights. The methods followed for all our market research studies include three significant steps – primary research, secondary research, and data modeling and analysis - to derive the current market size and forecast it over the forecast period. In this study, these three steps were used iteratively to generate valid data points (minimum deviation), which were cross-validated through multiple approaches mentioned below in the data modeling section.
Through secondary research methods, information on the market under study, its peer, and the parent market was collected. This information was then entered into data models. The resulted data points and insights were then validated by primary participants.
Based on additional insights from these primary participants, more directional efforts were put into doing secondary research and optimize data models. This process was repeated till all data models used in the study produced similar results (with minimum deviation). This way, this iterative process was able to generate the most accurate market numbers and qualitative insights.
Secondary research
The secondary research sources that are typically mentioned to include, but are not limited to:
The paid sources for secondary research like Factiva, OneSource, Hoovers, and Statista
Primary Research:
Primary research involves telephonic interviews, e-mail interactions, as well as face-to-face interviews for each market, category, segment, and subsegment across geographies
The contributors who typically take part in such a course include, but are not limited to:
Data Modeling and Analysis:
In the iterative process (mentioned above), data models received inputs from primary as well as secondary sources. But analysts working on these models were the key. They used their extensive knowledge and experience about industry and topic to make changes and fine-tuning these models as per the product/service under study.
The standard data models used while studying this market were the top-down and bottom-up approaches and the company shares analysis model. However, other methods were also used along with these – which were specific to the industry and product/service under study.
To know more about the research methodology used for this study, kindly contact us/click here.
